Revolution Medicines
Targeted small-molecule inhibitors for RAS-driven cancers
- Sector
- Biotech
- Headquarters
- Redwood City, CA
- Founded
- 2014
- Latest Form D
- $100M, Nov 2019
- Total capital
- $204M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $204M
- 3 Form D · last Nov 2019
- 83 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2025
- Rank in peer group#43 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$100M
- Private capital raisedForm D · SEC · 2nd filing$56.4M
- Private capital raisedForm D · SEC · 1st filing$47.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#43 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexis A. BorisyDirectorNamed in SEC Form D filings
- Barbara A. WeberDirectorNamed in SEC Form D filings
- Elizabeth A. AndersonDirectorNamed in SEC Form D filings
- Laurence A. LaskyDirectorNamed in SEC Form D filings
- Luan A. WilfongExecutive OfficerNamed in SEC Form D filings
- Margaret A. HornExecutive OfficerNamed in SEC Form D filings
Show all 13 people
- Mark A. GoldsmithExecutive Officer, DirectorNamed in SEC Form D filings
- Michael A. BonneyDirectorNamed in SEC Form D filings
- Neil A. ExterDirectorNamed in SEC Form D filings
- Ryan A. MartinsExecutive OfficerNamed in SEC Form D filings
- Steve A. KelseyExecutive OfficerNamed in SEC Form D filings
- Thilo A. SchroederDirectorNamed in SEC Form D filings
- Vincent A. MillerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingRapamycin Analogs As Mtor InhibitorsUSPTOApplication 19339052
- PendingCompositions For Inducing Ras Gtp Hydrolysis And Uses ThereofUSPTOApplication 19339640
- PendingSHP2 Inhibitor Compositions And Methods For Treating CancerUSPTOApplication 19090050
Show all 40 patent records
- Rapamycin Analogs As Mtor InhibitorsSep 17, 2026 · Application 19339052Pending
- Compositions For Inducing Ras Gtp Hydrolysis And Uses ThereofSep 3, 2026 · Application 19339640Pending
- SHP2 Inhibitor Compositions And Methods For Treating CancerAug 13, 2026 · Application 19090050Pending
- C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsAug 6, 2026 · Application 19312078Pending
- Compounds That Participate In Cooperative Binding And Uses ThereofAug 6, 2026 · Application 19312611Pending
- Ras InhibitorsJul 16, 2026 · Application 19357383Pending
- Ras InhibitorsJul 16, 2026 · Application 19564448Pending
- Myc Amplification Drives Resistance To Pan-ras Inhibitors In Pancreatic CancerJun 23, 2026 · US 12,662,707Granted
- Macrocyclic Ras InhibitorsJun 11, 2026 · Application 19350374Pending
- Bicyclic Heteroaryl Compounds And Uses ThereofJun 4, 2026 · Application 19011414Pending
- Ras InhibitorsJun 4, 2026 · Application 19460508Pending
- Methods Of Treating CancerMay 28, 2026 · Application 18880867Pending
- Composition Comprising A First Ras Inhibitor, Second Ras Inhibitor And A SHP2 Inhibitor For Use In The Treatment Of CancerMay 28, 2026 · Application 19120279Pending
- Ras InhibitorsMay 12, 2026 · US 12,624,053Granted
- Methods Of Treating A Ras Protein-related Disease Or DisorderApr 23, 2026 · Application 19363949Pending
- Bicyclic Compounds As Allosteric SHP2 InhibitorsApr 16, 2026 · Application 19243902Pending
- Ras InhibitorsMar 19, 2026 · Application 19396666Pending
- Ras InhibitorsMar 12, 2026 · Application 19388266Pending
- 2,5-DISUBSTITUTED 3-METHYL Pyrazines And 2,5,6-TRISUBSTITUTED 3-METHYL Pyrazines As Allosteric SHP2 InhibitorsMar 3, 2026 · US 12,565,476Granted
- Combination Therapy For A Ras Related Disease Or DisorderFeb 26, 2026 · Application 19377386Pending
- Ras InhibitorsFeb 12, 2026 · Application 19269349Pending
- C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsFeb 10, 2026 · US 12,544,448Granted
- Methods Of Treating Cancer With An Mtor InhibitorFeb 3, 2026 · US 12,539,305Granted
- Macrocyclic Ras InhibitorsJan 29, 2026 · Application 19350302Pending
- Solid Forms Of {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, A SHP2 InhibitorJan 20, 2026 · US 12,528,807Granted
- Ras InhibitorsDec 25, 2025 · Application 19308717Pending
- Methods Of Treating A Ras Protein-related Disease Or DisorderDec 11, 2025 · Application 19230256Pending
- Ras InhibitorsDec 4, 2025 · Application 19044266Pending
- Ras InhibitorsNov 27, 2025 · Application 19003004Pending
- Methods Of Treating A Ras Related Disease Or DisorderNov 13, 2025 · Application 19219571Pending
- Ras InhibitorsNov 11, 2025 · US 12,465,643Granted
- Ras InhibitorsOct 16, 2025 · Application 19196483Pending
- Pyrazolopyrazine Compounds As SHP2 InhibitorsSep 11, 2025 · Application 18720331Pending
- Ras InhibitorsSep 9, 2025 · US 12,409,225Granted
- Ras InhibitorsSep 2, 2025 · US 12,403,196Granted
- Compounds, Complexes, And Methods For Their Preparation And Of Their UseAug 28, 2025 · Application 19200842Pending
- Ras InhibitorsAug 14, 2025 · Application 19196471Pending
- Ras InhibitorsAug 12, 2025 · US 12,384,750Granted
- Substituted Pyrazolopyrazines, Imidazopyrazines And [1,2,4]TRIAZOLOPYRAZINES As Allosteric SHP2 InhibitorsJul 22, 2025 · US 12,365,688Granted
- Compounds That Participate In Cooperative Binding And Uses ThereofJun 26, 2025 · Application 18787714Pending
Related companies, and why
- Generation BioSimilar federal contract value in Biotech · null in contracts
- Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NovaBay PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- TrueBinding, Inc.Similar federal contract value in Biotech · null in contracts
- Bright Peak TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .